Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

Researchers estimated that the total hospitalization cost associated with a serious infection in CLL was $19,184. For patients with chronic lymphocytic leukemia (CLL), the hospitalization costs ...

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. It is characterized by the accumulation of mature monoclonal B lymphocytes. While native kidney infiltration in CLL is ...

In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the US Food and Drug Administration (FDA) for adults with relapsed or refractory ...

Credit: Getty Images The latest data released at ASH 2025 highlight how targeted therapies are changing the way CLL is managed. Significant treatment options with targeted therapies are changing the ...

In the world of oncology drug development, the standard playbook is simple: Race to earlier lines of treatment, where patient populations are larger. But Eli Lilly is flipping that script with its ...

Jaypirca improved progression-free survival in CLL/SLL patients compared to bendamustine plus rituximab, reducing disease progression or death risk by 80%. This non-covalent BTK inhibitor offers a ...

Treatment of chronic lymphocytic leukemia (CLL) currently consists of two main approaches — continuous therapy with Bruton’s tyrosine kinase inhibitors and fixed-duration regimens combining venetoclax ...

Please provide your email address to receive an email when new articles are posted on . Adding ianalumab to ibrutinib allowed many patients with CLL to stop daily ibrutinib for 1 to 2 years. More than ...